Grape seed extract supplementation in non-alcoholic fatty liver disease

被引:2
|
作者
Ghanbari, Parisa [1 ]
Alboebadi, Roghayeh [1 ]
Bazyar, Hadi [2 ,3 ]
Raiesi, Davoud [4 ]
Zarejavid, Ahmad [5 ]
Azadbakht, Mohammad Karim [6 ]
Karimi, Mahdi [1 ]
Razmi, Hamidreza [1 ]
机构
[1] Ahvaz Jundishapur Univ Med Sci, Student Res Comm, Ahvaz, Iran
[2] Sirjan Sch Med Sci, Dept Publ Hlth, Sirjan, Iran
[3] Student Res Comm, Sirjan Sch Med Sci, Sirjan, Iran
[4] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Internal Med, Ahvaz, Iran
[5] Ahvaz Jundishapur Univ Med Sci, Clin Sci Res Inst, Nutr & Metab Dis Res Ctr, Ahvaz, Iran
[6] Sirjan Sch Med Sci, Dept Basic Sci, Sirjan, Iran
关键词
non-alcoholic fatty liver disease; oxidative stress; quality of life; grape seed extract; ANTIOXIDANT STATUS; OXIDATIVE STRESS; DOUBLE-BLIND; INCREASES; QUESTIONNAIRE; POLYPHENOLS; VALIDATION;
D O I
10.1024/0300-9831/a000805
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Despite rising non-alcoholic fatty liver disease (NAFLD) prevalence and its impact on liver health, there's a lack of studies on grape seed extract's (GSE) effect on oxidative stress and quality of life (QoL) in NAFLD patients. This study aims to fill this gap by the potential benefits of GSE in reducing oxidative stress and improving QoL. Methods: In this randomized clinical trial study, fifty patients with NAFLD were randomly assigned to receive either 2 tablets of GSE containing 250 mg of proanthocyanidins or placebo (25 participants in each group) for two months. QoL was evaluated using the SF-36 questionnaire, and oxidative stress variables (TAC, MDA, SOD, GPx, CAT, and IL-6) were measured at the beginning and end of the study. Results: Compared with the control group, the group supplemented with GSE experienced greater reductions in IL-6 and MDA (3.14 +/- 1.43 pg/ml vs. 2.80 +/- 0.31 pg/ml; 4.16 +/- 2.09 mu M vs. 4.59 +/- 1.19 mu M, p for all <0.05), as well as greater increases in TAC, SOD, and GPx levels (0.18 +/- 0.08 mM vs. -0.03 +/- 0.09 mM; 10.5 +/- 6.69 U/ml vs. 8.93 +/- 1.63 U/ml; 14.7 +/- 13.4 U/ml vs. 8.24 +/- 3.03 U/ml, p for all <0.05). Furthermore, the QoL questionnaire showed that physical limitations, general health, and total physical health were significantly improved in the GSE group compared with the placebo (17.0 +/- 42.0 vs. -12.0 +/- 37.5; 3.80 +/- 14.8 vs. -3.92 +/- 9.55; 5.08 5.26 vs. -7.01 +/- 13.7, p for all <0.05). Conclusions: GSE can be effective in improving oxidative stress and QoL in patients with NAFLD. More studies are needed to confirm the results of this study.
引用
收藏
页码:365 / 376
页数:12
相关论文
共 50 条
  • [1] The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease
    Del Ben, Maria
    Polimeni, Licia
    Baratta, Francesco
    Pastori, Daniele
    Angelico, Francesco
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (01) : 88 - 95
  • [2] Non-alcoholic fatty liver disease and lipotoxicity
    Wasilewska, Natalia
    Lebensztejn, Dariusz Marek
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2021, 7 (01) : 1 - 6
  • [3] Atherosclerosis and Non-Alcoholic Fatty Liver Disease
    Balta, Sevket
    ANGIOLOGY, 2022, 73 (08) : 701 - 711
  • [4] The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study
    Ghanbari, Parisa
    Raiesi, Davoud
    Alboebadi, Roghayeh
    Zarejavid, Ahmad
    Dianati, Mostafa
    Razmi, Hamidreza
    Bazyar, Hadi
    BMC COMPLEMENTARY MEDICINE AND THERAPIES, 2024, 24 (01)
  • [5] Effects of green coffee extract supplementation on blood pressure and antioxidants status in patients with non-alcoholic fatty liver disease
    Hosseinabadi, Samaneh
    Rafraf, Maryam
    Asgbari-Jafarabadi, Mohammad
    PROGRESS IN NUTRITION, 2019, 21 : 180 - 189
  • [6] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [7] Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
    Ramai, Daryl
    Facciorusso, Antonio
    Vigandt, Erika
    Schaf, Bryan
    Saadedeen, Waleed
    Chauhan, Aditya
    di Nunzio, Sara
    Shah, Aashni
    Giacomelli, Luca
    Sacco, Rodolfo
    CELLS, 2021, 10 (12)
  • [8] Preclinical models of non-alcoholic fatty liver disease
    Santhekadur, Prasanna K.
    Kumar, Divya P.
    Sanyal, Arun J.
    JOURNAL OF HEPATOLOGY, 2018, 68 (02) : 230 - 237
  • [9] An overview of ferroptosis in non-alcoholic fatty liver disease
    Wang, Shendong
    Liu, Zhaojun
    Geng, Jiafeng
    Li, Liangge
    Feng, Xiujing
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 153
  • [10] Iron overload and non-alcoholic fatty liver disease
    Datz, Christian
    Mueller, Elena
    Aigner, Elmar
    MINERVA ENDOCRINOLOGICA, 2017, 42 (02) : 173 - 183